Cargando…

Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens

The development and dissemination of antibiotic-resistant bacterial pathogens is a growing global threat to public health. Novel compounds and/or therapeutic strategies are required to face the challenge posed, in particular, by Gram-negative bacteria. Here we assess the combined effect of potent ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qian, Cebrián, Rubén, Montalbán-López, Manuel, Ren, Huan, Wu, Weihui, Kuipers, Oscar P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782785/
https://www.ncbi.nlm.nih.gov/pubmed/33398076
http://dx.doi.org/10.1038/s42003-020-01511-1
_version_ 1783631975862501376
author Li, Qian
Cebrián, Rubén
Montalbán-López, Manuel
Ren, Huan
Wu, Weihui
Kuipers, Oscar P.
author_facet Li, Qian
Cebrián, Rubén
Montalbán-López, Manuel
Ren, Huan
Wu, Weihui
Kuipers, Oscar P.
author_sort Li, Qian
collection PubMed
description The development and dissemination of antibiotic-resistant bacterial pathogens is a growing global threat to public health. Novel compounds and/or therapeutic strategies are required to face the challenge posed, in particular, by Gram-negative bacteria. Here we assess the combined effect of potent cell-wall synthesis inhibitors with either natural or synthetic peptides that can act on the outer-membrane. Thus, several linear peptides, either alone or combined with vancomycin or nisin, were tested against selected Gram-negative pathogens, and the best one was improved by further engineering. Finally, peptide D-11 and vancomycin displayed a potent antimicrobial activity at low μM concentrations against a panel of relevant Gram-negative pathogens. This combination was highly active in biological fluids like blood, but was non-hemolytic and non-toxic against cell lines. We conclude that vancomycin and D-11 are safe at >50-fold their MICs. Based on the results obtained, and as a proof of concept for the newly observed synergy, a Pseudomonas aeruginosa mouse infection model experiment was also performed, showing a 4 log(10) reduction of the pathogen after treatment with the combination. This approach offers a potent alternative strategy to fight (drug-resistant) Gram-negative pathogens in humans and mammals.
format Online
Article
Text
id pubmed-7782785
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-77827852021-01-11 Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens Li, Qian Cebrián, Rubén Montalbán-López, Manuel Ren, Huan Wu, Weihui Kuipers, Oscar P. Commun Biol Article The development and dissemination of antibiotic-resistant bacterial pathogens is a growing global threat to public health. Novel compounds and/or therapeutic strategies are required to face the challenge posed, in particular, by Gram-negative bacteria. Here we assess the combined effect of potent cell-wall synthesis inhibitors with either natural or synthetic peptides that can act on the outer-membrane. Thus, several linear peptides, either alone or combined with vancomycin or nisin, were tested against selected Gram-negative pathogens, and the best one was improved by further engineering. Finally, peptide D-11 and vancomycin displayed a potent antimicrobial activity at low μM concentrations against a panel of relevant Gram-negative pathogens. This combination was highly active in biological fluids like blood, but was non-hemolytic and non-toxic against cell lines. We conclude that vancomycin and D-11 are safe at >50-fold their MICs. Based on the results obtained, and as a proof of concept for the newly observed synergy, a Pseudomonas aeruginosa mouse infection model experiment was also performed, showing a 4 log(10) reduction of the pathogen after treatment with the combination. This approach offers a potent alternative strategy to fight (drug-resistant) Gram-negative pathogens in humans and mammals. Nature Publishing Group UK 2021-01-04 /pmc/articles/PMC7782785/ /pubmed/33398076 http://dx.doi.org/10.1038/s42003-020-01511-1 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Li, Qian
Cebrián, Rubén
Montalbán-López, Manuel
Ren, Huan
Wu, Weihui
Kuipers, Oscar P.
Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title_full Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title_fullStr Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title_full_unstemmed Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title_short Outer-membrane-acting peptides and lipid II-targeting antibiotics cooperatively kill Gram-negative pathogens
title_sort outer-membrane-acting peptides and lipid ii-targeting antibiotics cooperatively kill gram-negative pathogens
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782785/
https://www.ncbi.nlm.nih.gov/pubmed/33398076
http://dx.doi.org/10.1038/s42003-020-01511-1
work_keys_str_mv AT liqian outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens
AT cebrianruben outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens
AT montalbanlopezmanuel outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens
AT renhuan outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens
AT wuweihui outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens
AT kuipersoscarp outermembraneactingpeptidesandlipidiitargetingantibioticscooperativelykillgramnegativepathogens